FDMT - Company ID 0001650648
The table below shows 4D Molecular Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$109.08M | -$134.59M | -$75.79M | -$86.69M | -$69.13M | -$50.91M |
| Capital expenditure | $536.00K | $3.79M | $2.77M | $11.54M | $9.11M | $1.00M |
| Investing cash flow | -$92.97M | -$302.44M | $115.72M | -$17.05M | -$172.68M | -$1.00M |
| Dividends paid | - | - | - | - |
4D Molecular Therapeutics, Inc. reported operating cash flow of -$109.08M for fiscal year 2025. That is up 18.9% from -$134.59M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$36.71M (FY 2019) to -$109.08M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $112.96M | $337.25M | $156.83M | $3.08M | $118.09M | $278.98M |